Navigation Links
Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
Date:8/19/2007

ANNAPOLIS, Md., Aug. 17 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (Amex: PIP) announced today that a hearing has been scheduled by the Delaware Court of Chancery for 2:00 p.m. on Monday, August 27, 2007, in an action filed by PharmAthene stockholder Matthew P. Kinley pursuant to Section 225(b) of the Delaware General Corporation Law seeking a determination from the Delaware Court of Chancery that the merger between PharmAthene, Inc. and Healthcare Acquisition Corp. (the "Merger") was validly approved at the Special Meeting of Stockholders of Healthcare Acquisition Corp. on August 3, 2007 and thereafter consummated by the filing of a Certificate of Merger with the Delaware Secretary of State. By this press release, PharmaAthene is providing notice to all holders of the common stock of PharmAthene, Inc. (formerly known as Healthcare Acquisition Corp.) of the pending judicial action in the Delaware Court of Chancery.

As previously disclosed in the press release dated August 6, 2007, the tabulation of the number of shares demanding conversion into a right to receive cash rather than shares in the post-merger entity was initially misreported to the Special Meeting of Stockholders of Healthcare Acquisition Corp. by its transfer agent. Following that misreporting, certain of the officers, directors and stockholders of Healthcare Acquisition Corp. and certain stockholders of PharmAthene purchased additional shares of common stock of Healthcare Acquisition Corp., reducing the number of conversion elections and allowing for consummation of the Merger. In his Complaint, PharmAthene stockholder Matthew P. Kinley alleges that the stockholder action taken at the Special Meeting of Stockholders of Healthcare Acquisition Corp. on August 3, 2007 was sufficient to approve the Merger. PharmAthene has consummated the Merger in accordance with the wishes of over 75% of Healthcare Acquisition Corp.'s stockholders who voted in favor of the Merger, but the board of directors of PharmAthene has made a determination to refrain from releasing the funds held in trust to PharmAthene absent a determination by the Delaware Court of Chancery that the Merger was validly approved and consummated. Accordingly, Plaintiff Matthew P. Kinley, a substantial stockholder of PharmAthene, commenced litigation in the Delaware Court of Chancery to determine the validity of the Merger.

During the hearing before the Delaware Court of Chancery at 2:00 p.m. on Monday, August 27, 2007, Plaintiff Matthew P. Kinley will ask the Court to issue a final order and judgment ruling that the Merger was validly approved and consummated in accordance with Delaware law. If granted, the final order and judgment would be binding on PharmAthene and all former, current and future stockholders of PharmAthene. Any stockholder who wishes to object to the Delaware Court of Chancery's confirmation of the validity of the Merger must either submit an objection in writing prior to the hearing or must appear in person or by counsel at the hearing. Failure to submit a timely objection or to appear at the hearing may preclude later challenge to the validity and consummation of the Merger. If you have any questions or concerns, you are urged to contact the PharmAthene representative listed below for more information.

The action filed by Plaintiff Matthew P. Kinley is captioned Matthew P. Kinley v. Healthcare Acquisition Corp., n/k/a PharmAthene, Inc., C.A. No. 3161-CC. A copy of the Complaint can be obtained from PharmAthene. The Answer to the Complaint that PharmAthene has filed admits the facts alleged therein and agrees that the request for judicial determination under 225(b) of the Delaware General Corporation Law is appropriate. The location where the hearing will be conducted, as well as the address to which any objections are to be delivered, is as follows:

Delaware Court of Chancery

New Castle County Courthouse

500 North King Street

Wilmington, DE 19801

Copies of any written objections should also be served on the following attorneys of record in the pending action:

John L. Reed, Esq.

Edwards Angell Palmer & Dodge LLP

919 N. Market Street, 15th Floor

Wilmington, DE 19801

(302) 777-7770

Counsel for the Plaintiff

Christopher A. Selzer, Esq.

McCarter & English, LLP

405 N. King Street

Wilmington, DE 19801

(302) 984-6300

Counsel for PharmAthene

Additional Information

PHARMATHENE CLAIMS THE PROTECTION OF THE SAFE HARBOR FOR "FORWARD- LOOKING STATEMENTS" WITHIN THE MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. FORWARD-LOOKING STATEMENTS ARE STATEMENTS THAT ARE NOT HISTORICAL FACTS. SUCH FORWARD-LOOKING STATEMENTS, BASED UPON THE CURRENT BELIEFS AND EXPECTATIONS OF MANAGEMENT OF PHARMATHENE REGARDING, AMONG OTHER THINGS, THE POTENTIAL DETERMINATIONS BY A COURT OF CHANCERY IN DELAWARE AS TO THE VALIDITY OF THE APPROVAL OF THE MERGER, WHICH CANNOT BE PREDICTED WITH CERTAINTY. NO ASSURANCES CAN BE GIVEN THAT OTHER PARTIES WILL NOT OPPOSE CONFIRMATION OF SUCH VALIDITY. IN THE EVENT THAT THE DELAWARE COURT OF CHANCERY DOES NOT AFFIRM SUCH VALIDITY, PHARMATHENE COULD BE REQUIRED TO LIQUIDATE ANY FUNDS THEN HELD IN TRUST. THIS PROCEEDING WILL NOT AFFECT THE DISTRIBUTION OF THE TRUST FUND TO STOCKHOLDERS WHO ELECTED CONVERSION.

About PharmAthene, Inc.

PharmAthene is a biodefense company formed in 2001 to meet the critical needs of the United States by developing biodefense products. PharmAthene is dedicated to the rapid development of important and novel biotherapeutics to address biological pathogens and chemicals that may be used as weapons of bioterror. PharmAthene's lead programs include Valortim(TM) and Protexia(R). For more information on PharmAthene, please visit its website at http://www.PharmAthene.com.


'/>"/>
SOURCE PharmAthene, Inc.

Copyright©2007 PR Newswire.

Related biology technology :

1. Green County courts to hold hearings via video conferencing
2. Public Hearing Held for controversial anti-cloning bills
3. Delaware company will keep NameProtect here
4. Wisconsin Supreme Court to hear Menasha software case
5. Supreme Court limits foreign reach of U.S. patents
6. High court sends message on patent obviousness
7. Supreme Court ruling seen as blow to WARF stem cell patents
8. Software tax dispute could go the Supreme Court
9. Wisconsin court halts Abbotts sale of genotyping products
10. Wisconsin court affirms damages in Innogenetics, Abbott patent case
11. With patents, Wisconsin court gaining reputation as a "rocket docket"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... 23, 2016 , ... UAS LifeSciences, one of the leading ... UP4™ Probiotics, into Target stores nationwide. The company, which has been manufacturing high ... its list of well-respected retailers. This list includes such fine stores as Whole ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
(Date:6/23/2016)... , June 23, 2016 Houston ... with the Cy-Fair Sports Association to serve as ... the agreement, Houston Methodist Willowbrook will provide sponsorship ... and connectivity with association coaches, volunteers, athletes and ... with the Cy-Fair Sports Association and to bring ...
(Date:6/23/2016)... June 23, 2016  The Prostate Cancer Foundation (PCF) is pleased ... and faster cures for prostate cancer. Members of the Class of 2016 were ... Read More About the Class of 2016 PCF Young ... ... ...
Breaking Biology Technology:
(Date:4/15/2016)... CHICAGO , April 15, 2016  A ... companies make more accurate underwriting decisions in a ... offering timely, competitively priced and high-value life insurance ... health screenings. With Force Diagnostics, rapid ... and lifestyle data readings (blood pressure, weight, pulse, ...
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting ... are setting a new clinical standard in telehealth thanks ... By leveraging the higi platform, IMPOWER patients can routinely ... pulse and body mass index, and, when they opt ... and convenient visit to a local retail location at ...
(Date:3/29/2016)... 29, 2016 LegacyXChange, Inc. (OTC: ... and SelectaDNA/CSI Protect are pleased to announce our successful ... a variety of writing instruments, ensuring athletes signatures against ... collectibles from athletes on LegacyXChange will be assured of ... DNA. Bill Bollander , CEO states, ...
Breaking Biology News(10 mins):